Evolocumab, Repatha, LDL, ACC late breaker, best LDL lowering drug

March 20, 2017 — The most important late-breaking pharmaceutical trial at the 2017 America College of Cardiology annual meeting this weekend was FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk). Evolocumab (Repatha), one of the new targeted PCSK9 inhibitor drugs has been show to dramatically lower levels of low-density lipoprotein (LDL) and significantly lower cardiovascular events in patients with existing heart or vascular disease already on statin therapy. 

March 17, 2017 - Transcatheter aortic valve replacement (TAVR) was found to be noninferior to surgical aortic valve replacement (SAVR) in intermediate risk patients according to data presented today for the late-breaking SURTAVI Trial. The primary composite endpoint of all-cause mortality and disabling stroke at 24 months was similar for patients with symptomatic, severe aortic stenosis who had an intermediate level of operative risk.

W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a dual-component stent with a fluoropolymer/nitinol design. The device, which gained CE Mark approval in 2011, is a third-generation, self-expanding stent that was designed explicitly to improve anatomical conformability with the natural movement of the knee when treating peripheral artery disease (PAD).

Alcohol abuse increases the risk of atrial fibrillation, heart attack and congestive heart failure as much as other well-established risk factors, according to a study published recently in the Journal of the American College of Cardiology.

During the 66th Annual Scientific Session & Expo of the American College of Cardiology (ACC), March 17-19 in Washington, D.C., Siemens Healthineers will showcase technologies that integrate images and information at every step of the treatment process, with a theme of “Making Complex Simple.”

A new document from the American Society of Echocardiography (ASE) provides a comprehensive update to guide clinicians in best practices for assessing all forms of valvular regurgitation.

Medtronic plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Reveal LINQ Insertable Cardiac Monitor (ICM) with TruRhythm Detection. The advanced cardiac monitor offers improved accuracy to better identify abnormal heartbeats.

The U.S. Food and Drug Administration (FDA) has cleared the Artis pheno robotic C-arm angiography system from Siemens Healthineers created for use in minimally invasive interventional procedures.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now